

CITATION REPORT

List of articles citing

Methotrexate in psoriasis: revised guidelines

DOI: 10.1016/s0190-9622(88)80237-8

Journal of the American Academy of Dermatology,
1988, 19, 145-56.

Source: <https://exaly.com/paper-pdf/19856827/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
335	Methotrexate in rheumatoid arthritis. <i>Journal of the American Academy of Dermatology</i> , 1988 , 19, 126-8	4.5	29
334	Treatment of rheumatoid arthritis. 1989 , 2, S23-32		7
333	Purine metabolism as a target for leukemia chemotherapy. 1989 , 3, 162-73		20
332	Erythrodermic psoriasis. <i>Journal of the American Academy of Dermatology</i> , 1989 , 21, 985-991	4.5	102
331	Pharmacology. II. Systemic drugs in dermatology. <i>Journal of the American Academy of Dermatology</i> , 1989 , 21, 298-305	4.5	
330	Methotrexate. 1989 , 7, 128-35		6
329	Long-term methotrexate treatment in corticosteroid-dependent asthma. 1990 , 112, 577-81		84
328	Methotrexate side-effects. 1990 , 122 Suppl 36, 127-33		43
327	Pneumocystis carinii pneumonia following methotrexate. 1990 , 122, 291		5
326	Methotrexate and trimethoprim-sulphamethoxazole--a potentially hazardous combination. 1990 , 15, 358-60		64
325	Therapeutic and Immunologic Advances in Psoriasis. 1990 , 3, 3-16		
324	Methotrexate and Liver Biopsies. 1990 , 150, 733		7
323	Methotrexate-Induced Cirrhosis Requiring Liver Transplantation in Three Patients With Psoriasis. 1990 , 150, 889		49
322	Multiple Rheumatoid Nodules of the Renal Cortex. 1990 , 150, 891		7
321	The practical use of methotrexate in psoriasis. 1990 , 40, 697-712		15
320	Psoriasis in practice. 1991 , 338, 231-4		31
319	The pharmacology of methotrexate. <i>Journal of the American Academy of Dermatology</i> , 1991 , 25, 306-18	4.5	126

318	Serum aminoterminal propeptide of type III procollagen in psoriasis and psoriatic arthritis: relation to liver fibrosis and arthritis. <i>Journal of the American Academy of Dermatology</i> , 1991 , 25, 50-3	4.5	54
317	From traditional to problem-based curriculum: how the switch was made at Sherbrooke, Canada. 1991 , 338, 234-7		26
316	Low-dose weekly methotrexate for unusual neutrophilic vascular reactions: cutaneous polyarteritis nodosa and Behçet's disease. <i>Journal of the American Academy of Dermatology</i> , 1991 , 24, 973-8	4.5	86
315	Dermatologic drugs in pregnancy. 1991 , 9, 435-51		3
314	Weekly low-dose methotrexate therapy for cutaneous sarcoidosis. <i>Journal of the American Academy of Dermatology</i> , 1991 , 24, 451-4	4.5	96
313	Hydroxyurea therapy. <i>Journal of the American Academy of Dermatology</i> , 1991 , 25, 518-24	4.5	93
312	Guidelines for management of patients with psoriasis. Workshop of the Research Unit of the Royal College of Physicians of London; Department of Dermatology, University of Glasgow; British Association of Dermatologists. 1991 , 303, 829-35		39
311	Low-dose methotrexate therapy and hepatotoxicity The view of the hepatologist. 1991 , 155, 428-430		6
310	Neutropenia due to low-dose methotrexate therapy for psoriasis and rheumatoid arthritis may be fatal. 1991 , 155, 480-4		38
309	Cytotoxic drugs in the treatment of skin disease. 1991 , 30, 313-22		16
308	Treatment of pemphigus. 1991 , 30, 139-46		33
307	Methotrexate in asthma. 1991 , 21, 541-3		9
306	Hepatotoxicity in a rat model caused by orally administered methotrexate. 1991 , 14, 906-10		34
305	Treatment of Psoriasis With Piritrexim, a Lipid-Soluble Folate Antagonist. 1991 , 127, 511		7
304	History of the treatment of psoriasis. <i>Journal of the American Academy of Dermatology</i> , 1992 , 27, 640-5	4.5	35
303	Monitoring for adverse effects from systemic drugs used in dermatology. <i>Journal of the American Academy of Dermatology</i> , 1992 , 26, 661-79	4.5	24
302	The efficacy of methotrexate in psoriasis—a review of 40 cases. 1992 , 17, 257-60		61
301	Liver biopsy versus ultrasound in methotrexate-treated psoriasis: a decision analysis. 1992 , 31, 404-9		16

300	Dynamic hepatic scintigraphy in the screening of psoriatic patients for methotrexate-induced hepatotoxicity. 1992 , 127, 122-5		21
299	Methotrexate and non-steroidal anti-inflammatory drugs. 1992 , 126, 95		6
298	Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis. 84-month update. 1992 , 35, 129-37		198
297	A multicentre 12-week open study of a lipid-soluble folate antagonist, piritrexim in severe psoriasis. 1993 , 129, 584-9		13
296	The annual cost of psoriasis. <i>Journal of the American Academy of Dermatology</i> , 1993 , 28, 422-5	4.5	111
295	Methotrexate in asthma. A safety perspective. 1993 , 9, 151-5		7
294	1992 AAD Award for Excellence in Education: The Integrated Basic and Clinical Science Conference Series at the University of Texas Southwestern Medical Center. <i>Journal of the American Academy of Dermatology</i> , 1993 , 29, 761-72	4.5	5
293	Toxicity of paracetamol in cultured chick hepatocytes treated with methotrexate. 1993 , 228, 289-98		2
292	Liver fibrosis quantified by image analysis in methotrexate-treated patients with psoriasis. <i>Journal of the American Academy of Dermatology</i> , 1993 , 28, 40-5	4.5	24
291	Guidelines of care for psoriasis. Committee on Guidelines of Care. Task Force on Psoriasis. <i>Journal of the American Academy of Dermatology</i> , 1993 , 28, 632-7	4.5	37
290	Severe megaloblastic anemia in a patient receiving low-dose methotrexate for psoriasis. <i>Journal of the American Academy of Dermatology</i> , 1993 , 29, 477-80	4.5	16
289	Methotrexate with leucovorin rescue: A therapeutic alternative in severe psoriatics with a history of methotrexate-induced pancytopenia and diminished renal or hepatic function. 1993 , 4, 145-148		1
288	Use of methotrexate for psoriasis in Wales. 1993 , 4, 161-162		1
287	Bioequivalence of two methotrexate formulations in psoriatic and cancer patients. 1993 , 27, 1434-8		2
286	The carcinogenic risk of treatments for severe psoriasis. Photochemotherapy Follow-up Study. 1994 , 73, 2759-64		362
285	Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology. 1994 , 37, 316-28		489
284	Second-line drug therapy for rheumatoid arthritis. 1994 , 330, 1368-75		136
283	Methotrexate revisited: effects of long-term treatment in psoriasis. 1994 , 130, 204-10		137

282	The value of a baseline liver biopsy prior to methotrexate treatment. 1994 , 131, 891-4		5
281	Skin lesions in psoriasis. 1994 , 8, 295-316		8
280	Therapeutic progress. II: Treatment of psoriasis. 1994 , 19, 223-32		11
279	Methotrexate in childhood psoriasis. 1994 , 11, 271-3		89
278	Abdominal sonogram may prevent complications from liver biopsy. <i>Journal of the American Academy of Dermatology</i> , 1994 , 31, 690-1	4-5	1
277	Monitoring patients taking methotrexate for hepatotoxicity. Does the standard of care match published guidelines?. <i>Journal of the American Academy of Dermatology</i> , 1994 , 31, 969-77	4-5	18
276	Letters. 1994 , 34, 3		2
275	End-stage liver disease developing with the use of methotrexate in heterozygous alpha 1-antitrypsin deficiency. 1995 , 38, 1014-8		12
274	Usefulness of the American College of Rheumatology recommendations for liver biopsy in methotrexate-treated rheumatoid arthritis patients. 1995 , 38, 1115-9		66
273	The combination of ursodeoxycholic acid and methotrexate for patients with primary biliary cirrhosis: The results of a pilot study. 1995 , 22, 1158-1162		53
272	Methotrexate hepatotoxicity and the role of routine liver biopsy: a collective opinion. 1995 , 36, 228-9		1
271	Methotrexate and Other Chemotherapeutic Agents Used to Treat Psoriasis. 1995 , 13, 875-890		22
270	Future Psoriasis Therapy. 1995 , 13, 915-923		2
269	Assessing the Preferences of Patients With Psoriasis. 1995 , 131, 561		52
268	An audit of the use of methotrexate in a dermatology department. 1995 , 6, 179-182		1
267	Methotrexate for chronic diseases in adults. 1995 , 332, 330-1		43
266	Treatment of psoriasis. 1995 , 333, 258; author reply 258-9		1
265	Another truly presidential checkup. 1995 , 333, 260-1		7

264	Are semen quality and male fertility changing?. 1995 , 332, 327-8		61
263	Can lowering homocysteine levels reduce cardiovascular risk?. 1995 , 332, 328-9		169
262	Methotrexate for chronic diseases in adults. 1995 , 332, 1791; author reply 1791-2		
261	Interval cytoreduction in ovarian cancer. 1995 , 333, 254; author reply 255		10
260	Interval cytoreduction in ovarian cancer. 1995 , 333, 255		5
259	More on skin cancer after the extravasation of doxorubicin. 1995 , 333, 257		1
258	Patients with Chronic Diarrhea. 1995 , 333, 257-258		
257	Recombinant tissue plasminogen activator for prosthetic mitral-valve thrombosis. 1995 , 333, 259		4
256	Metaphors and health care reform. 1995 , 333, 259-60		
255	Staging of head and neck cancer. 1995 , 332, 1787-8; author reply 1789-90		1
254	Extensive extraspinal hyperostoses after long-term oral retinoid treatment in a patient with pityriasis rubra pilaris. <i>Journal of the American Academy of Dermatology</i> , 1995 , 32, 322-5	4-5	33
253	Treatment of dermatomyositis with methotrexate. <i>Journal of the American Academy of Dermatology</i> , 1995 , 32, 754-7	4-5	61
252	A comparative study of cognitive behavior therapy versus general anesthesia for painful medical procedures in children. 1995 , 62, 3-9		83
251	Treatment of psoriasis. 1995 , 332, 581-8		284
250	The combination of ursodeoxycholic acid and methotrexate for patients with primary biliary cirrhosis: the results of a pilot study. 1995 , 22, 1158-62		67
249	Safety Considerations with Cyclosporin and Other Systemic Therapy in the Treatment of Severe Psoriasis. 1995 , 10, 36-44		5
248	Major adverse effects from systemic drugs: Defining the risks. 1995 , 7, 6-38		11
247	Methotrexate for inflammatory bowel disease: pharmacology and preliminary results. 1996 , 71, 69-80		69

246	Low-dose methotrexate to treat erythrodermic cutaneous T-cell lymphoma: results in twenty-nine patients. <i>Journal of the American Academy of Dermatology</i> , 1996 , 34, 626-31	4.5	104
245	Behçet's disease. Report of twenty-five patients from the United States with prominent mucocutaneous involvement. <i>Journal of the American Academy of Dermatology</i> , 1996 , 34, 745-50	4.5	58
244	Methotrexate is effective therapy for lymphomatoid papulosis and other primary cutaneous CD30-positive lymphoproliferative disorders. <i>Journal of the American Academy of Dermatology</i> , 1996 , 34, 470-81	4.5	132
243	Use of methotrexate in older patients. A risk-benefit assessment. 1996 , 9, 458-71		17
242	Immunosuppressive Agents in Skin Disorders. 1996 , 5, 268-293		10
241	10. Psoriasis. 1996 , 165, 216-221		4
240	Methotrexate hepatotoxicity in psoriatics: report of 104 patients from Nova Scotia, with analysis of risks from obesity, diabetes and alcohol consumption during long term follow-up. 1996 , 10, 369-75		108
239	What is New in the Treatment of Psoriasis?. 1996 , 7, 255-259		
238	Methotrexate-induced liver cirrhosis. Clinical, histological and serological studies--a further 10-year follow-up. 1996 , 192, 343-6		58
237	Review article: methotrexate in gastroenterology--dangerous villain or simply misunderstood?. 1996 , 10, 851-8		17
236	The value of dynamic hepatic scintigraphy and serum aminoterminal propeptide of type III procollagen for early detection of methotrexate-induced hepatic damage in psoriasis patients. 1996 , 134, 481-487		7
235	Serum type III procollagen aminopeptide for assessing liver damage in methotrexate-treated psoriatic patients. 1996 , 135, 538-544		16
234	Methotrexate for psoriasis. 1996 , 21, 399-408		59
233	Methotrexate and liver toxicity: role of surveillance liver biopsy. Conflict between guidelines for rheumatologists and dermatologists. 1996 , 55, 273-5		20
232	A 47-Year-Old Man With Asymptomatic Hepatitis C Infection, 1 Year Later. 1996 , 276, 1428		
231	A 61-Year-Old Man With Psoriasis. 1996 , 276, 1421		2
230	Methotrexate therapy and liver disease. 1996 , 335, 898-9		4
229	Methotrexate update. 1996 , 25, 341-4		32

228	The management of psoriasis. 1996 , 34, 17-9		3
227	The expanding role of the nurse in rheumatology. 1997 , 36, 410-2		10
226	Immunopharmacology. 1997 , 278, 2008		34
225	Therapy for psoriatic arthritis: sometimes a conflict for psoriasis. 1997 , 36, 409-10		21
224	Current Management of Psoriasis. 1997 , 8, 27-55		31
223	Current Thoughts on the Use of Methotrexate in Patients with Psoriasis. 1997 , 2, 41-46		3
222	[Not Available]. 1997 , 7, 85-90		
221	Methotrexate use in psoriasis and psoriatic arthritis. <i>Rheumatic Disease Clinics of North America</i> , 1997 , 23, 797-809	2.4	30
220	Methotrexate hepatotoxicity. <i>Rheumatic Disease Clinics of North America</i> , 1997 , 23, 883-915	2.4	94
219	Psoriasis. 1997 , 2, 78-80		0
218	Methotrexate. 1997 , 15, 781-97		39
217	Low-dose methotrexate administered weekly is an effective corticosteroid-sparing agent for the treatment of the cutaneous manifestations of dermatomyositis. <i>Journal of the American Academy of Dermatology</i> , 1997 , 36, 67-71	4.5	76
216	Clinical safety of tazarotene in the treatment of plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 1997 , 37, S25-S32	4.5	16
215	Asthme chronique grave : place des traitements immunosuppresseurs. 1997 , 37, 312-315		
214	Systemic treatment of severe psoriasis. 1997 , 38, 171-80; quiz 181-2		5
213	Intermittent, short term use of methotrexate for exacerbations of psoriasis. 1997 , 36, 954-5		1
212	A systematic review of five systemic treatments for severe psoriasis. 1997 , 137, 943-949		22
211	The long-term effect of methotrexate therapy on the liver in patients with juvenile rheumatoid arthritis. 1997 , 40, 2226-34		54

210	Management of cutaneous lupus erythematosus with low-dose methotrexate: indication for modulation of inflammatory mechanisms. 1998 , 18, 59-62	76
209	Methotrexate hepatotoxicity: what is the evidence?. 1998 , 47, 148-51	16
208	Renal function after 10 years' treatment with cyclosporin for psoriasis. 1998 , 138, 443-9	68
207	Methotrexate in psoriasis: consensus conference. <i>Journal of the American Academy of Dermatology</i> , 1998 , 38, 478-85	4.5 288
206	Psoriasis treatment. 1998 , 10, 1-40	9
205	Reactions and interactions of some commonly used systemic drugs in dermatology. 1998 , 16, 421-9	14
204	Psoriasis. 1998 , 82, 1135-44, vi	4
203	Immunosuppressive agents in dermatology. An update. 1998 , 16, 235-51	65
202	Recognition and treatment of psoriasis. Special considerations in elderly patients. 1998 , 12, 177-90	22
201	Use of cytotoxic agents and cyclosporine in the treatment of autoimmune disease. Part 2: Inflammatory bowel disease, systemic vasculitis, and therapeutic toxicity. 1998 , 129, 49-58	57
200	Urinary adenosine and aminoimidazolecarboxamide excretion in methotrexate-treated patients with psoriasis. 1999 , 135, 813-7	33
199	The role of salicylic acid in the treatment of psoriasis. 1999 , 38, 16-24	93
198	Dead-Sea climatotherapy versus other modalities of treatment for psoriasis: comparative cost-effectiveness. 1999 , 38, 252-62	24
197	[Ulcerative stomatitis as clinical clue to inadvertent methotrexate overdose]. 1999 , 50, 670-3	14
196	Alcohol interactions with drugs and its effect on the treatment of skin diseases. 1999 , 17, 443-5	1
195	The relationship of hepatotoxic risk factors and liver histology in methotrexate therapy for juvenile rheumatoid arthritis. 1999 , 134, 47-52	42
194	Risk of melanoma with psoralen/ultraviolet A therapy for psoriasis. Do the known risks now outweigh the benefits?. 1999 , 20, 289-97	21
193	Low-dose methotrexate is ineffective in primary biliary cirrhosis: long-term results of a placebo-controlled trial. 1999 , 117, 400-7	74

192	Methotrexate in refractory Crohn's disease. 1999 , 5, 11-5		32
191	Pulmonary function changes in patients with psoriasis on methotrexate therapy. 1999 , 26, 423-7		2
190	Psoriasis associated with HCV and exacerbated by interferon alpha: complete clearance with acitretin during interferon alpha treatment for chronic active hepatitis. 2000 , 201, 179-81		30
189	Methotrexate in psoriasis: 26 years' experience with low-dose long-term treatment. 2000 , 14, 382-8		96
188	Hepatic fibrosis in rheumatoid arthritis patients treated with methotrexate: application of a new semi-quantitative scoring system. 2000 , 39, 50-4		22
187	Liver biopsies and methotrexate: a time for reconsideration?. <i>Journal of the American Academy of Dermatology</i> , 2000 , 42, 531-4	4-5	46
186	Risk-benefit assessment of methotrexate in the treatment of severe psoriasis. 2000 , 1, 27-39		33
185	Methotrexate in Crohn's disease: long-term efficacy and toxicity. 2000 , 95, 1730-4		38
184	Hepatic effects of long-term methotrexate use in the treatment of inflammatory bowel disease. 2000 , 95, 3150-6		137
183	Other novel immunosuppressants. 2000 , 18, 475-83, ix		7
182	Comparative tolerability of treatments for inflammatory bowel disease. 2000 , 23, 429-48		135
181	Methotrexate in Crohn's disease: long-term efficacy and toxicity. 2000 , 95, 1730-1734		83
180	Treatment of psoriasis. Part 2. Systemic therapies. <i>Journal of the American Academy of Dermatology</i> , 2001 , 45, 649-61; quiz 662-4	4-5	158
179	Antimetabolites and cytotoxic drugs. 2001 , 19, 105-18, viii-ix		15
178	Liver biopsy in psoriatic arthritis to detect methotrexate hepatotoxicity. 2001 , 7, 224-7		15
177	Successful treatment of a patient with lymphomatoid papulosis by methotrexate. 2001 , 28, 373-8		7
176	The value of amino-terminal propeptide of type III procollagen in routine screening for methotrexate-induced liver fibrosis: a 10-year follow-up. 2001 , 144, 100-3		87
175	A clinical study to determine the efficacy and safety of 1% methotrexate/Azone (MAZ) gel applied topically once daily in patients with psoriasis vulgaris. 2001 , 40, 464-7		29

174	Lymphomatoid papulosis associated with Sjögren's syndrome. 2002 , 29, 174-7	6
173	Comparative tolerability of systemic treatments for plaque-type psoriasis. 2002 , 25, 913-27	55
172	Light and electron microscopic analysis of liver biopsy samples from rheumatoid arthritis patients receiving long-term methotrexate therapy. 2002 , 31, 330-6	19
171	Tratamiento de la psoriasis pustulosa palmoplantar. 2002 , 17, 500-503	1
170	A case with hepatic fibrosis showing ascites and esophageal varices induced by oral UFT(R) administration. 2002 , 22, 161-165	5
169	Traditional therapies: glucocorticoids, azathioprine, methotrexate, hydroxyurea. 2002 , 27, 546-54	27
168	Short-term methotrexate therapy in psoriasis: a study of 197 patients. 2002 , 41, 444-8	33
167	Traditionelle Therapien: Glukokortikoide, Azathioprin, Methotrexat, Hydroxyharnstoff. 2002 , 77, 624-632	1
166	26. Immunomodulation and immunotherapy: drugs, cytokines, cytokine receptors, and antibodies. 2003 , 111, S720-43	44
165	Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. 2003 , 349, 658-65	388
164	Low dose methotrexate in inflammatory bowel disease: current status and future directions. 2003 , 98, 530-7	51
163	Alefacept is well tolerated in patients with chronic plaque psoriasis. 2004 , 8 Suppl 2, 14-9	7
162	Tratamento sistémico da psoríase - Parte I: metotrexato e acitretina. 2004 , 79, 263-278	10
161	Therapy treatment options for psoriasis: topical and systemic. <i>Therapy: Open Access in Clinical Medicine</i> , 2004 , 1, 319-330	2
160	Treatment of ocular inflammation in children. 2004 , 6, 289-301	15
159	Rheumatoid arthritis: more aggressive approach improves outlook. 2004 , 71, 409-13	12
158	Dermoscopy of pigmented purpuric dermatoses (lichen aureus): a useful tool for clinical diagnosis. 2004 , 140, 1290-1	50
157	Analysis of risk factors in psoriatic patients with methotrexate-induced increases in transaminase levels. 2004 , 140, 1289-90	4

156	Review article: the evolving role of liver biopsy. 2004 , 20, 249-59		81
155	Alefacept Is Well Tolerated in Patients with Chronic Plaque Psoriasis. 2004 , 8, 15-19		3
154	Monitoring methotrexate-induced hepatic fibrosis in patients with psoriasis: are serial liver biopsies justified?. 2004 , 19, 391-9		79
153	Efficacy of conventional immunosuppressive drugs in IBD. 2004 , 36, 766-80		12
152	Methotrexate and psoriasis in the era of new biologic agents. <i>Journal of the American Academy of Dermatology</i> , 2004 , 50, 301-9	4-5	46
151	Drug Reactions. 3765-3944		1
150	Understanding psoriatic arthritis. 2005 , 66, 163-7		
149	Methotrexate, dermatologie et rhumatologie. 2005 , 72, 180-181		
148	Methotrexate for psoriasis: current European practice. A postal survey. 2005 , 19, 196-202		17
147	Review article: monitoring of immunomodulators in inflammatory bowel disease. 2005 , 21, 307-19		55
146	Review article: practical management of inflammatory bowel disease patients taking immunomodulators. 2005 , 22, 1-16		88
145	Monitoring patients on methotrexate: hepatic fibrosis not seen in patients with normal serum assays of aminoterminal peptide of type III procollagen. 2005 , 152, 451-8		54
144	Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks. 2005 , 152, 597-615		146
143	The potential of pharmacogenetics in optimizing the use of methotrexate for psoriasis. 2005 , 153, 869-73		21
142	Pilot trial: Pioglitazone versus placebo in patients with plaque psoriasis (the P6). 2005 , 44, 328-33		66
141	Methotrexate in dermatology and rheumatology. 2005 , 72, 104-5		3
140	Systemic treatment for moderate to severe psoriasis: estimates of failure rates and direct medical costs in a north-eastern US managed care plan. 2005 , 16, 37-42		26
139	Monitoring liver function during methotrexate therapy for psoriasis: are routine biopsies really necessary?. 2005 , 6, 357-63		33

138 Methotrexate. **2006**, 2277-2290

137 Fulfilling an unmet need in psoriasis : do biologicals hold the key to improved tolerability?. **2006**, 29, 49-66 35

136 Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy. **2006**, 17, 9-17 99

135 A treatment strategy for psoriasis: transitioning from systemic therapy to biologic agents. **2006**, 5, 285-8 15

134 Efficacy and tolerability of multiple-dose SDZ IMM 125 in patients with severe psoriasis. **1995**, 133, 95-103 10

133 Sequential liver biopsies during long-term methotrexate treatment for psoriasis: a reappraisal. **1995**, 133, 774-8 67

132 Dermatology in the intensive care unit. **1995**, 132, 226-35 16

131 Diagnosis of liver fibrosis by transient elastography (FibroScan) and non-invasive methods in Crohn's disease patients treated with methotrexate. **2006**, 23, 1621-8 58

130 Hepatotoxicity of chemotherapy. **2006**, 33, 50-67 176

129 Painless electroporation with a new needle-free microelectrode array to enhance transdermal drug delivery. **2006**, 110, 557-65 52

128 Bullöse Arzneimittelreaktion im Bereich subkutaner Methotrexat-Injektionen. **2006**, 32, 371-375

127 Methotrexate-betamethasone weekly oral pulse in psoriasis. **2007**, 18, 291-4 10

126 Medical management of Crohn's disease. **2007**, 20, 269-81 9

125 Role of methotrexate in the management of Crohn disease. **2007**, 44, 427-30 27

124 Dermatologic disorders associated with chronic hepatitis C: effect of interferon therapy. **2007**, 5, 142-51 41

123 Psoriatic arthritis: current concepts on pathogenesis-oriented therapeutic options. **2007**, 56, 1051-66 47

122 Transitioning patients from efalizumab to alternative psoriasis therapies: findings from an open-label, multicenter, Phase IIIb study. **2007**, 46, 637-48 28

121 Methotrexate in dermatology. **2007**, 20, 216-28 60

120	Case series analysis of psoriatic arthritis: a two-centre experience. 2007 , 10, 32-36		
119	Assessment of publications using methods of evidence-based medicine: an introduction using a dermatological clinical study. 2007 , 5, 793-800		2
118	Literaturbewertung mit Instrumenten der evidenzbasierten Medizin: eine Einführung anhand einer dermatologischen Therapiestudie. 2007 , 5, no-no		
117	[Quality and quantity in hepatopathology. Diagnostic and clinically relevant grading for non-tumourous liver diseases]. 2008 , 29, 15-26		5
116	Gene expression profiles of murine fatty liver induced by the administration of methotrexate. 2008 , 249, 75-84		16
115	Methotrexate: prescribing and monitoring practices among the consultant membership of the British Association of Dermatologists. 2008 , 158, 793-800		16
114	[The liver and methotrexate]. 2008 , 32, 134-42		16
113	Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. <i>Journal of the American Academy of Dermatology</i> , 2008 , 58, 826-50	4.5	958
112	Systemic therapies for psoriasis: methotrexate, retinoids, and cyclosporine. 2008 , 26, 438-47		59
111	Moderate-to-Severe Psoriasis. 2008 ,		
110	Avonex Combination Trial in relapsing--remitting MS: rationale, design and baseline data. 2008 , 14, 370-82		21
109	The pathology of drug-induced liver injury. 2009 , 29, 364-72		85
108	Hepatotoxicity rates do not differ in patients with rheumatoid arthritis and psoriasis treated with methotrexate. 2009 , 48, 1107-10		42
107	Methotrexate poisoning. 2009 , 8, 89-92		1
106	Efficacy of methotrexate in Crohn's disease and ulcerative colitis patients unresponsive or intolerant to azathioprine /mercaptopurine. 2009 , 30, 614-20		73
105	Ustekinumab: a new option in psoriasis therapy. 2009 , 69, 1141-52		29
104	Histological patterns in drug-induced liver disease. 2009 , 62, 481-92		201
103	Evaluation and management of psoriasis: an internist's guide. 2009 , 93, 1291-303		39

102	Drug Reactions. 2010 , 1-177	24
101	Psoriasis. 2010 , 1-60	24
100	[Portal hypertension in patients with inflammatory bowel disease]. 2010 , 33, 297-302	1
99	Drug-Induced Liver Disease. 2011 , 703-783	4
98	Liver Injury Due to Drugs and Herbal Agents. 2011 , 311-352	
97	A Case of Cutaneous Side Effect of Methotrexate Mimicking Behçet's Disease. 2011 , 23, 412-4	4
96	Assessment and management of methotrexate hepatotoxicity in psoriasis patients: report from a consensus conference to evaluate current practice and identify key questions toward optimizing methotrexate use in the clinic. 2011 , 25, 758-64	61
95	Monitoring methotrexate hepatotoxicity in psoriasis. 2011 , 77, 545-8	1
94	Skin and Bone Disorders. 2012 , 319-349	1
93	Serum interleukin-6 levels in response to methotrexate treatment in psoriatic patients. 2012 , 413, 1652-6	25
92	Hepatic injury due to drugs, herbal compounds, chemicals and toxins. 2012 , 645-760	12
91	Significant clinical risks and the benefits of liver biopsies in Srinagarind Hospital, Khon Kaen University, Thailand: Lessons learned from the past to the present. <i>Interventional Medicine & Applied Science</i> , 2012 , 4, 92-97	0.7
90	History of Methotrexate and Use in Psoriasis. 2012 , 18a, 164-173	
89	The use of methotrexate in dermatology: a review. 2012 , 53, 1-18	63
88	Methotrexate. 2013 , 339-343	
87	Cutaneous dermatomyositis: an updated review of treatment options and internal associations. 2013 , 14, 291-313	46
86	Histopathological Evaluation of Drug-Induced Liver Disease. 2013 , 241-263	2
85	Association of disease severity with IL-1 levels in methotrexate-treated psoriasis patients. 2013 , 78, 545-53	21

84	Evaluation of therapeutic response of methotrexate and calcipotriol combination compared with methotrexate alone in plaque psoriasis. 2014 , 5, 118-123	
83	Nicht invasive versus invasive Beurteilung der Leberfibrose. 2014 , 10, 51-67	1
82	End-stage methotrexate-related liver disease is rare and associated with features of the metabolic syndrome. 2014 , 40, 938-48	31
81	Impact of methotrexate on oxidative stress and apoptosis markers in psoriatic patients. 2014 , 14, 431-7	39
80	Cytostatic and cytotoxic drugs. 2014 , 821-861	2
79	Prolonged remission of psoriasis with azathioprine pulse therapy. 2014 , 11, 213-216	1
78	Magnetic resonance elastography and transient elastography as non-invasive analyses for liver fibrosis: can they obviate the need for liver biopsy in psoriasis patients treated with methotrexate?. 2015 , 54, 752-6	34
77	To Biopsy or not to Biopsy: A Review of Guidelines on the use of Methotrexate. 2015 , 1, 31-37	
76	An unusual case of acute methotrexate toxicity manifesting as ulcers on psoriatic plaques in an elderly male. 2015 , 71, S22-5	0
75	Apremilast. 2016 , 75-82	
74	The expanding role of methotrexate for treating skin disease. 2016 , 175, 9-10	5
73	Methotrexate. 2016 , 886-911	1
72	Topical and Systemic Therapies for Moderate-to-Severe Psoriasis. 2016 , 253-266	1
71	Psoriatic Arthritis and Psoriasis. 2016 ,	3
70	Relative risk of and determinants for adverse events of methotrexate prescribed at a low dose: a systematic review and meta-analysis of randomized placebo-controlled trials. 2017 , 177, 978-986	25
69	Conventional Medical Management of Crohn's Disease: Methotrexate. 2017 , 333-342	0
68	Protective effects of Balanites aegyptiaca extract, Melatonin and Ursodeoxycholic acid against hepatotoxicity induced by Methotrexate in male rats. 2017 , 10, 557-565	15
67	Methotrexate Hepatotoxicity and the Impact of Nonalcoholic Fatty Liver Disease. 2017 , 354, 172-181	31

66	Cytoprotective effects of molsidomine against methotrexate-induced hepatotoxicity: an experimental rat study. 2019 , 13, 13-21	11
65	Current pharmacological treatment guidelines for psoriasis and psoriatic arthritis. 2018 , 11, 1209-1218	12
64	Targeting the IL-23/IL-17 Pathway in Psoriasis: the Search for the Good, the Bad and the Ugly. 2018 , 19, 625-637	7
63	Drugs and Toxins. 2018 , 673-779	9
62	Liver Injury Due to Drugs and Herbal Agents. 2018 , 327-370	0
61	Risankizumab for the treatment of psoriasis. 2019 , 12, 851-857	3
60	Hematological, hepatic, and renal adverse effects of high dose methotrexate injection (50 mg weekly) in severe psoriasis cases. 2019 ,	0
59	Chaulmoogra oil based methotrexate loaded topical nanoemulsion for the treatment of psoriasis. 2019 , 49, 463-476	38
58	[Drug-induced liver injury-significance of pathology]. 2020 , 41, 457-470	
57	Hepascore predicts liver outcomes and all-cause mortality in long-term methotrexate users: A retrospective cohort study. 2020 , 4, 1211-1216	1
56	Overview of Dual-Acting Drug Methotrexate in Different Neurological Diseases, Autoimmune Pathologies and Cancers. 2020 , 21,	60
55	Long-term Safety of Oral Systemic Therapies for Psoriasis: A Comprehensive Review of the Literature. 2020 , 10, 589-613	14
54	A pragmatic non-invasive assessment of liver fibrosis in patients with psoriasis, rheumatoid arthritis or Crohn's disease receiving methotrexate therapy. 2020 , 44S, 100003	1
53	Glycoconjugation as a Promising Treatment Strategy for Psoriasis. 2020 , 373, 204-212	6
52	Methotrexate. 1999 , 45S, 341-2	1
51	Erythematöse, erythemosquamöse und papulöse Hauterkrankungen. 1996 , 523-611	1
50	Psoriasis. 1995 , 265-304	0
49	Methotrexate. 2011 , 509-517.e3	2

48	HEPATOTOXICITY OF CHEMOTHERAPEUTIC AND ONCOLOGIC AGENTS. 1995 , 24, 969-990		44
47	Serum type III procollagen aminopeptide for assessing liver damage in methotrexate-treated psoriatic patients. 1996 , 135, 538-544		35
46	The value of dynamic hepatic scintigraphy and serum aminoterminal propeptide of type III procollagen for early detection of methotrexate-induced hepatic damage in psoriasis patients. 1996 , 134, 481-487		15
45	A systematic review of five systemic treatments for severe psoriasis. 1997 , 137, 943-949		56
44	New Horizons in Hydrogels for Methotrexate Delivery. 2020 , 7,		14
43	Prolonged Remission of Psoriasis with Azathioprine Pulse Therapy. 2015 , 60, 360-3		4
42	Acute Methotrexate Toxicity Due to Overdosing in Psoriasis: A Series of Seven Cases. <i>Indian Dermatology Online Journal</i> , 2019 , 10, 64-68	0.9	2
41	Alkyl-Terminated Gold Nanoparticles as a Self-Therapeutic Treatment for Psoriasis. 2021 , 21, 8723-8733		3
40	Psoriasis. 2002 , 313-362		
39	Skin and Bone Disorders. 2006 , 327-357		2
38	Management of psoriasis. 2009 , 102, 631-6		
37	Histopathological Scoring Systems. 2010 , 271-288		
36	Psoriasis. 2010 , 193-205		
35	DRUGS USED IN CANCER CHEMOTHERAPY. 2010 , 1-229		
34	GLUCOCORTICOIDS AND DISEASE MODIFYING ANTIRHEUMATIC DRUGS. 2010 , 371-667		
33	Oral Disease and Oral-Cutaneous Manifestations of Gastrointestinal and Liver Disease. 2010 , 353-369.e2		
32	Conventional Medical Management of Crohn's Disease: Methotrexate. 2012 , 387-395		
31	METHOTREXATE: ADVERSE REACTIONS AND MAJOR TOXICITIES. <i>Rheumatic Disease Clinics of North America</i> , 1994 , 20, 513-528	2.4	58

30 Rheologica: Pentoxifyllin. **1995**, 171-176

29 TREATMENT OF REFRACTORY PSORIATIC ARTHRITIS. *Rheumatic Disease Clinics of North America*, **1995**, 21, 129-149 2.4 5

28 Innerliche Behandlung von Dermatosen. **1996**, 1533-1551

27 Hepatotoxicity of Immunomodulating Agents. *Handbook of Experimental Pharmacology*, **1996**, 581-609 3.2

26 Drug-Induced Hepatotoxicity. **1998**, 163-190

25 Stevens Johnson Syndrome-Toxic Epidermal Necrolysis Overlap Secondary to Interaction Between Methotrexate and Etoricoxib: A Case Report. *Journal of Clinical and Diagnostic Research JCDR*, **2015**, 9, FD01-3 0 6

24 Drug-Related Steatohepatitis/Phospholipidosis. **2017**, 158-161

23 Methotrexate. **2017**, 383-388

22 Safety of TNF inhibitors in rheumatic disease in case of NAFLD and cirrhosis. *Seminars in Arthritis and Rheumatism*, **2020**, 50, 544-548 5.3 2

21 Olive Oil Based Methotrexate Loaded Topical Nanoemulsion Gel for the Treatment of Imiquimod Induced Psoriasis-like Skin Inflammation in an Animal Model. *Biology*, **2021**, 10, 4.9 4

20 Medikamentös-toxischer Leberschaden (DILI). *Pathologie*, **2020**, 117-157 0

19 Methotrexate Therapy. **2008**, 379-386

18 Significant clinical risks and the benefits of liver biopsies in Srinagarind Hospital, Khon Kaen University, Thailand: Lessons learned from the past to the present. *Interventional Medicine & Applied Science*, **2012**, 4, 92-97 0.7

17 Therapy treatment options for psoriasis: topical and systemic. *Therapy: Open Access in Clinical Medicine*, **2004**, 1, 319-330 0

16 Seborrhea, Psoriasis and the Papulosquamous Dermatoses. *Primary Care - Clinics in Office Practice*, **1989**, 16, 739-763 2.2 3

15 Expression of Th1 and Th2 Cytokine and Associated Transcription Factors in Peripheral Blood Mononuclear Cells and Correlation with Disease Severity. *Reports of Biochemistry and Molecular Biology*, **2017**, 6, 102-111 1.3 5

14 The Effect of Biological Agents on Antinuclear Antibody Status in Patients with Psoriasis: A Single-Center Study. *Indian Dermatology Online Journal*, **2020**, 11, 904-909 0.9

13 Toxic Epidermal Necrolysis-Like Lesions as Cutaneous Manifestation of Acute Methotrexate Toxicity. *Indian Dermatology Online Journal*, **2021**, 12, 340-341 0.9

12	The effect of biological agents on antinuclear antibody status in patients with psoriasis: A single-center study. <i>Indian Dermatology Online Journal</i> , 2020 , 11, 904	0.9	1
11	Toxic epidermal necrolysis-like lesions as cutaneous manifestation of acute methotrexate toxicity. <i>Indian Dermatology Online Journal</i> , 2021 , 12, 340	0.9	1
10	Immunomodulatory Effect of Methotrexate Abruptly Controls Keratinocyte Activation in Psoriasis.		
9	Clinical safety of tazarotene in the treatment of plaque psoriasis. 1997 , 37, S25-S32		0
8	Chlorquinaldol inhibits the activation of nucleotide-binding oligomerization domain-like receptor family pyrin domain-containing protein 3 inflammasome and ameliorates imiquimod-induced psoriasis-like dermatitis in mice. 2022 , 365, 110122		
7	Overview of Methotrexate Toxicity: A Comprehensive Literature Review. 2022 ,		0
6	Microneedle-mediated drug delivery for cutaneous diseases. 10,		1
5	Busting the myth of methotrexate chronic hepatotoxicity.		0
4	THE MANAGEMENT OF PSORIASIS. 1998 , 52, 487-491		1
3	Methotrexate. 2023 , 401-406		0
2	Methotrexate-induced liver fibrosis: The end of a long-held belief. 2023 , 78, 896-897		0
1	Hepatic Injury due to Drugs, Dietary and Herbal Supplements, Chemicals and Toxins. 2024 , 726-841		0